This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Ironwood Pharmaceuticals (IRWD) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Ironwood (IRWD) delivered earnings and revenue surprises of 9.09% and 3.82%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
United Therapeutics (UTHR) Q1 Earnings Miss, Sales Beat
by Zacks Equity Research
United Therapeutics (UTHR) reports mixed first-quarter 2021 results. Higher sales of Orenitram, Unituxin and Tyvaso offset lower sales of Remodulin and Adcirca.
Deciphera (DCPH) Q1 Loss Narrower Than Expected, Revenues Beat
by Zacks Equity Research
Deciphera (DCPH) posts a narrower loss in the first quarter while sales beat on the encouraging uptake of Qinlock.
Bausch's (BHC) Q1 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Bausch (BHC) beats on earnings but misses on sales in the first quarter due to the ongoing pandemic.
Esperion (ESPR) Q1 Earnings Miss, Lower Drug Price Hits Sales
by Zacks Equity Research
Esperion Therapeutics (ESPR) reports dismal first-quarter results as it misses estimates for earnings and sales. Stock down.
Pacira's (PCRX) Q1 Earnings Lag Estimates, Revenues Beat
by Zacks Equity Research
Pacira's (PCRX) earnings in the first quarter of 2021 miss estimates while revenues beat the same. Exparel sales rise year over year.
Viatris (VTRS) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Investors will look forward to regular top and bottom-line numbers and updates on the merger synergies when Viatris (VTRS) reports Q1 results.
Tilray (TLRY) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Investors will focus on revenue growth and other pipeline updates, when Tilray (TLRY) reports first-quarter 2021 results.
Will Eylea & Dupixent Drive Regeneron's (REGN) Q1 Earnings?
by Zacks Equity Research
Investors are likely to focus on the performance of Eylea and Dupixent along with other pipeline updates when Regeneron (REGN) reports first-quarter 2021 results.
Cambium (CMBM) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Cambium's (CMBM) first-quarter 2021 earnings are likely to have been driven by robust demand for superior broadband connectivity supported by a dynamic business model.
Aviat (AVNW) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Aviat's (AVNW) earnings in third-quarter fiscal 2021 are likely to have benefited from the increasing market traction of its microwave transport product and software offerings.
Is a Beat in Store for T-Mobile (TMUS) This Earnings Season?
by Zacks Equity Research
T-Mobile's (TMUS) revenues in the first quarter of 2021 are likely to have benefited from the Sprint merger and customer growth.
Ironwood Pharmaceuticals (IRWD) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Ironwood (IRWD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is a Beat in the Cards for Twist (TWS) This Earnings Season?
by Zacks Equity Research
Investors will focus on the top-line and bottom-line numbers when Twist (TWST) reports fiscal second-quarter 2021 results.
Ironwood (IRWD) Up 20.4% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Ironwood (IRWD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Ironwood (IRWD) Q4 Earnings Beat on Solid Linzess Sales
by Zacks Equity Research
Ironwood (IRWD) witnesses strong demand for Linzess in the fourth quarter. However, outlook for 2021 misses market expectations.
Ironwood Pharmaceuticals (IRWD) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Ironwood (IRWD) delivered earnings and revenue surprises of 33.33% and 9.56%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Ironwood Pharmaceuticals (IRWD) Q4 Earnings Expected to Decline
by Zacks Equity Research
Ironwood (IRWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Altimmune (ALT) Begins Phase II Study for Chronic Hepatitis B
by Zacks Equity Research
Altimmune (ALT) enrolls the first patient in a phase II study evaluating HepTcell for the treatment of patients with chronic hepatitis B. Shares rise.
Ocular's (OCUL) sNDA for Dextenza Gets FDA Acceptance, Shares Up
by Zacks Equity Research
The FDA accepts Ocular's (OCUL) sNDA for label expansion of Dextenza to treat ocular itching associated with allergic conjunctivitis. The FDA will give its verdict in October 2021. Shares rise.
J&J (JNJ) Begins Rolling BLA Filing of Multiple Myeloma Drug
by Zacks Equity Research
J&J (JNJ) initiates the rolling submission of its BLA to the FDA for BCMA CAR-T therapy, ciltacabtagene autoleucel to treat adults with relapsed/refractory multiple myeloma.
Ensign Group (ENSG) Rewards Shareholders With Dividend Hike
by Zacks Equity Research
Ensign Group's (ENSG) latest dividend hike indicates strong financial standing and continuous focus on boosting shareholders' value.
Karyopharm's (KPTI) Xpovio Gets FDA Nod for Second-Line Myeloma
by Zacks Equity Research
Karyopharm (KPTI) gets FDA approval for label expansion of its marketed drug, Xpovio, in combination with Takeda's Velcade and dexamethasone for treating multiple myeloma in second-line setting.
Ironwood (IRWD) Up 19.7% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Ironwood (IRWD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
JAZZ's Zepzelca Combo SCLC Study Fails, Drug Still Promising
by Zacks Equity Research
JAZZ announces the failure of a combination regimen of SCLC drug, Zepzelca, to meet primary endpoint in a late-stage study. However, overall study data seems promising for the drug. Stock up.